SEC Comment Letter for Propanc Biopharma, Inc. (PPCB) (CIK 0001517681) (PPCB) — Oct 25, 2018
Propanc Biopharma, Inc. (PPCB) (CIK 0001517681)
Date: Oct. 25, 2018 · CIK: 0001517681 · Accession: 0000000000-18-033495
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227877
Letter
October 25, 2018 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC, 3124 Australia Re:Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed October 17, 2018 File No. 333-227877 Dear Mr. Nathanielsz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Jonathan R. Shechter, Esq.
Show Raw Text
October 25, 2018
James Nathanielsz
Chief Executive Officer
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC, 3124
Australia
Re:Propanc Biopharma, Inc.
Registration Statement on Form S-1
Filed October 17, 2018
File No. 333-227877
Dear Mr. Nathanielsz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jonathan R. Shechter, Esq.